Free Trial

ImmuCell Q4 2023 Earnings Report

ImmuCell logo
$5.38 -0.12 (-2.18%)
As of 03:56 PM Eastern

ImmuCell EPS Results

Actual EPS
-$0.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ImmuCell Revenue Results

Actual Revenue
$5.10 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImmuCell Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

ImmuCell Earnings Headlines

A simple pattern that works in any market
Right when most traders were getting bearish, The All-Weather Pattern signaled something different. Following this setup could've turned every $1,000 into $1,770 in just 48 hours. But here's what really gets me excited... You don't need to be glued to your screen all day, no complex formulas, no guessing. Just wait for a stock to close below The All-Weather Pattern, then check if it opens higher the next morning. That's it. While of course I cannot promise future returns or against losses… I've put together a complete breakdown of how this works, including the new stock that’s tending towards The All-Weather Pattern this week.
See More ImmuCell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email.

About ImmuCell

ImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

View ImmuCell Profile

More Earnings Resources from MarketBeat